tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew Harrison, 538 are a BUY (60.38%), 272 are a HOLD (30.53%), 81 are a SELL (9.09%).
Analyst Matthew Harrison, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 66.47% that have a potential upside of 28.99% achieved within 216 days.
Matthew Harrison’s has documented 1,729 price targets and ratings displayed on 91 stocks. The coverage is on Healthcare, Technology, Basic Materials, Energy sectors.
Most recent stock forecast was given on REGN, Regeneron Pharmaceuticals at 02-Jun-2025.
Analyst best performing recommendations are on CMRX (CHIMERIX).
The best stock recommendation documented was for CMRX (CHIMERIX) at 2/23/2016. The price target of $5 was fulfilled within 1 day with a profit of $0.54 (12.11%) receiving and performance score of 121.08.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$8
$4.33 (117.98%)
$8
29 days ago
(15-May-2025)
0/8 (0%)
$6.31 (373.37%)
Buy
$8
$4.33 (117.98%)
$8
2 months 13 days ago
(31-Mar-2025)
1/12 (8.33%)
$6.59 (467.38%)
70
Buy
$7
$3.33 (90.74%)
2 months 13 days ago
(31-Mar-2025)
0/2 (0%)
$5.59 (396.45%)
Sell
$1
$-2.67 (-72.75%)
$2
1 years 7 months 27 days ago
(17-Oct-2023)
2/4 (50%)
$0.23 (29.87%)
30
Hold
$5
1 years 10 months 3 days ago
(10-Aug-2023)
1/2 (50%)
$-0.07 (-1.38%)
2
Which stock is Matthew Harrison is most bullish on?
Which stock is Matthew Harrison is most reserved on?
What Year was the first public recommendation made by Matthew Harrison?
